Synonyms: Azactam® | Cayston® | SQ 26776 | SQ-26776 | SQ26776
aztreonam is an approved drug (FDA (1986), EMA (2009))
Compound class:
Synthetic organic
Comment: Aztreonam is a monocyclic β-lactam antibacterial that is resistant to β-lactamase hydrolysis. It was isolated from Chromobacterium violaceum. Functionally it preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3) and thereby inhibits bacterial cell wall synthesis. Aztreonam was removed from the World Health Organization's List of Essential Medicines in 2019.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Aztreonam is used as a single agent to treat serious infections that are caused by susceptible gram-negative bacteria e.g. Citrobacter (including C. freundii), Enterobacter (including E. cloacae), E. coli, Klebsiella (including K. pneumoniae), Pseudomonas aeruginosa, or Serratia (including S. marcescens). In the EU, aztreonam (Cayston®) is indicated for the suppressive therapy of chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients. Aztreonam is being investigated in an intravenous fixed-dose combination with the β-lactamase inhibitor avibactam (ATM-AVI; PF-06947387) for the treatment of serious bacterial infections. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03580044 | Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria | Phase 3 Interventional | Pfizer |
External links |
For extended ADME data see the following: Drugs.com |